Rakovina Therapeutics Inc (RKV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has a cash flow conversion efficiency ratio of -0.548x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.04 Million ≈ $-748.85K USD) by net assets (CA$1.89 Million ≈ $1.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rakovina Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Rakovina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Rakovina Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Rakovina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rakovina Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Polycons Public Company Limited
BK:TPOLY
|
0.129x |
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
0.102x |
|
Mantex AB
ST:MANTEX
|
-1.685x |
|
ActiveOps PLC
LSE:AOM
|
-0.136x |
|
Liontrust Asset Management
LSE:LIO
|
0.056x |
|
OurLiving AB
ST:OURLIV
|
-4.139x |
|
Bohra Industries Limited
NSE:BOHRAIND
|
0.009x |
|
Goobit Group AB
ST:BTCX
|
0.705x |
Annual Cash Flow Conversion Efficiency for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Rakovina Therapeutics Inc from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Rakovina Therapeutics Inc (RKV) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-3.86 Million ≈ $-2.79 Million |
-0.897x | -76.29% |
| 2023-12-31 | CA$3.66 Million ≈ $2.65 Million |
CA$-1.86 Million ≈ $-1.35 Million |
-0.509x | -59.59% |
| 2022-12-31 | CA$6.01 Million ≈ $4.35 Million |
CA$-1.92 Million ≈ $-1.39 Million |
-0.319x | -17.99% |
| 2021-12-31 | CA$8.54 Million ≈ $6.18 Million |
CA$-2.31 Million ≈ $-1.67 Million |
-0.270x | -- |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more